Tragara Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Tragara Pharmaceuticals Inc. may have found a beneficial use for a COX-2 inhibitor in oncology, and it involves a urine test, not a biopsy, to match non-small cell lung cancer patients with the therapy. This profile was adapted from an article that first appeared in the July issue of Pharmaceuticals Approval Monthly.